# Liquid Biopsy Using Methylation Sequencing for Lung Cancer

> **NCT04253509** · — · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 280 (actual)

## Conditions studied

- Lung Cancer
- Diagnoses Disease

## Interventions

- **DIAGNOSTIC_TEST:** Circulating Tumor DNA Methylation Sequencing

## Key facts

- **NCT ID:** NCT04253509
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-03
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2022-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04253509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04253509, "Liquid Biopsy Using Methylation Sequencing for Lung Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04253509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*